Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Capital Expenditures data on record, last reported at -$7.4 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 126.45% year-over-year to -$7.4 million; the TTM value through Dec 2025 reached $3.7 million, down 87.63%, while the annual FY2025 figure was $3.7 million, 87.63% down from the prior year.
  • Capital Expenditures reached -$7.4 million in Q4 2025 per MRVI's latest filing, down from $2.9 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $46.0 million in Q3 2023 and bottomed at -$13.4 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $5.9 million, with a median of $2.9 million recorded in 2025.
  • Peak YoY movement for Capital Expenditures: tumbled 296.39% in 2022, then skyrocketed 1862.11% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at -$7.0 million in 2021, then skyrocketed by 317.05% to $15.3 million in 2022, then increased by 9.86% to $16.8 million in 2023, then surged by 65.8% to $27.9 million in 2024, then plummeted by 126.45% to -$7.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$7.4 million in Q4 2025, $2.9 million in Q3 2025, and $2.9 million in Q2 2025.